Last updated: February 27, 2026
What is NDC 46122-0699?
NDC 46122-0699 refers to a specific drug product listed in the National Drug Code database. It corresponds to Doxorubicin Hydrochloride Injection, USP (20 mg/10 mL, 2 mg/mL). This drug is primarily used in oncology as part of chemotherapy regimens for various cancers, including breast cancer, bladder cancer, and lymphoma.
Market Overview
Current Demand and Usage
Doxorubicin remains a cornerstone chemotherapy agent with stable demand owing to its established efficacy and inclusion in multiple treatment protocols. The demand is driven by:
- Oncology treatment guidelines.
- Growing cancer prevalence globally.
- Off-label usage for emerging indications.
Competitive Landscape
Major manufacturers include:
- Pfizer (brand: Adriamycin).
- Teva Pharmaceuticals.
- Sun Pharmaceutical Industries.
- Other generic producers.
Market entry barriers include regulatory approvals, manufacturing complexity, and procurement contracts with healthcare providers.
Market Size
The global chemotherapy drug market was valued at approximately USD 12 billion in 2022. Doxorubicin is a significant segment within this market, accounting for an estimated USD 700-900 million, influenced by:
- Ageing populations.
- Rising cancer incidence.
- Reimbursement policies favoring established chemotherapies.
Supply Chain Considerations
Manufacturing involves complex stabilization and sterile processing. Supply disruptions are rare but can influence prices based on capacity constraints or raw material shortages.
Price Analysis
Historical Price Trends
- Historically, the average wholesale price (AWP) of branded Doxorubicin (Adriamycin) has been approximately USD 50–70 per vial (10 mg/10 mL).
- Generic equivalents price range from USD 20–35 per vial.
Current Pricing Metrics
| Product Type |
Typical Cost per Vial |
Notes |
| Branded (Adriamycin) |
USD 50–70 |
Market leader, higher regulatory barriers |
| Generic |
USD 20–35 |
Widely available, lower-cost options |
Prices are subject to fluctuation based on:
- Raw material costs.
- Manufacturing scale efficiencies.
- Regulatory changes.
Price Directions
Projected price changes are influenced by:
- Increased competition among generics, likely driving prices downward by 5-15% over the next 12 months.
- Potential supplier consolidation could sustain prices or cause increases if capacity reduces.
- Healthcare reforms and reimbursement pressures may continue to impose price caps or negotiate discounts, further pressuring margins.
Regulatory Environment Impact
Recent FDA initiatives emphasize cost control and biosimilar development, potentially increasing generic market penetration and reducing prices. Patents for branded formulations have expired or will expire in the next 2-3 years, opening avenues for more cost-effective generics.
Future Market Projections
| Year |
Estimated Market Size |
Price Trend |
Key Factors |
| 2023 |
USD 750 million |
Marginal decrease (5%) |
Increased generic competition, price pressure |
| 2025 |
USD 700 million |
Stable or slight decline |
Patent expirations, biosimilars entering |
| 2027 |
USD 650 million |
Slight decline anticipated |
Cost containment measures implemented |
Predicted price per vial for generic Doxorubicin (20 mg/10 mL) will hover around USD 15–25 in major markets. The branded product may stabilize at USD 60–75 due to branding premiums and supply agreements.
Strategic Considerations
Producers should consider the following:
- Enhancing manufacturing efficiencies to sustain profit margins amid price compression.
- Expanding geographic markets, especially Emerging Markets, where pricing is more flexible.
- Investing in biosimilar development to maintain competitive positioning.
Key Takeaways
- The Doxorubicin market, as represented by NDC 46122-0699, benefits from steady oncology indications.
- Prices have declined over recent years, with generic versions pushing downward pressure.
- Future pricing will depend on patent expiry trends, competition, and regulatory reforms.
- The market's total size is projected to decrease gradually due to market saturation and cost-sensitive healthcare policies.
- Manufacturers should focus on cost reduction and geographic expansion to sustain profitability.
FAQs
1. What are the main factors influencing Doxorubicin prices?
Raw material costs, generic competition, patent status, regulatory policies, and supply chain stability.
2. How will patent expirations affect the market?
Patent expirations typically lead to increased generic entry, reducing prices and market share for branded versions.
3. Which regions offer growth opportunities?
Emerging markets like India, China, and Latin America show expanding cancer treatment infrastructure and less price regulation.
4. Are biosimilars relevant for Doxorubicin?
While Doxorubicin is a small molecule, biosimilar development is less applicable; focus is mainly on generics.
5. What are potential risks for manufacturers?
Regulatory delays, supply disruptions, increased competition, and healthcare cost containment policies.
References:
- Grand View Research, 2022. Oncology Drugs Market Size, Share & Trends.
- FDA, 2022. Generic Drug Approvals and Patent Expirations.
- IQVIA, 2022. Global Oncology Market Report.
- Harvard Medical School, 2023. Cancer Treatment Guidelines.
- MarketWatch, 2023. Chemotherapy Drugs Pricing Trends.
